ASX Announcements


 
    Change of directors interests * 3  
 
    Cleansing notice  
 
    Appendix 4C - quarterly  
 
    Appendix 2A  
 
    Kazia Corporate Presentation  
 
    Kazia licenses EVT801 from Evotec  
 
    Trading Halt  
 
    Kazia presents PK data for paxalisib at AACR meeting  
 
    Change in substantial holding  
 
    Change in substantial holding  
 
    Proposed issue of Securities - KZA  
 
    Proposed issue of Securities - KZA  
 
    Kazia licenses paxalisib to Simcere in Greater China  
 
    Trading Halt  
 
    Kazia March Newsletter  
 
    Appendix 2A  
 
    Proposed issue of Securities - KZA  
 
    Appendix 2A  
 
    Kazia licenses Cantrixil to Oasmia  
 
    Change in substantial holding  
 
    Proposed issue of Securities - KZA  
 
    Kazia half year accounts and Appx 4D  
 
    Change in substantial holding  
 
    Appendix 4C - quarterly  
 
    Kazia presents to ShareCafe Hidden Gems webinar  
 
    Kazia commences recruitment to GBM AGILE  
 
    Kazia presents to HCW BIOCONNECT  
 
    Appendix 3G Issue of staff options  
 
    Change in directors interest  
 
    Change in directors interests  
 
    Change in directors interests  
 
    Kazia receives $1.02m R&D cash rebate  
 
    Kazia presents to LD Micro Main Event  
 
    Change in substantial holding  
 
    paxalisib PNOC collaboration  
 
    Kazia releases Cantrixil top line final data  
 
    Kazia presentation to Bell Potter Healthcare Conference  
 
    Change in substantial holding  
 
    Change in substantial holding  
 
    Kazia investor briefing transcript  
 
    Change in substantial holding  
 
    Change in substantial holding  
 
    Kazia's paxalisib SNO data  
 
    Kazia presents to HCW Israel conference  
 
    Change in directors interests * 4  
 
    Kazia issue of options  
 
    Kazia Results of Annual General Meeting  
 
    Kazia AGM materials  
 
    Change in substantial holding  
 
    Kazia unmarketable parcel share sale facility  
 
    Quarterly Activities Report and Appendix 4C  
 
    Change in substantial holding  
 
    Becoming a substantial holder  
 
    Change in substantial holding  
 
    Kazia Appendix 2A retail offer  
 
    Change in substantial holding  
 
    Kazia Completion of Retail Offer  
 
    Kazia executes GBM Agile study agreement  
 
    Kazia change in directors interests * 4  
 
    Change in substantial holding  
 
    Becoming a substantial holder  
 
    Kazia Appendix 2A  
 
    Kazia letter to ineligible shareholders  
 
    Kazia retail entitlement offer booklet  
 
    Kazia Notice of AGM and updated proxy form  
 
    Kazia Investor Webinar  
 
    Update - Proposed issue of Securities - KZA  
 
    Kazia successfully completes institutional entitlement offer  
 
    Kazia Cleansing Notice  
 
    Proposed issue of Securities - KZA  
 
    Kazia Investor Presentation  
 
    Kazia launch of Entitlement Offer  
 
    Trading Halt  
 
    Kazia Notice of Annual General Meeting/Proxy Form  
 
    Kazia Notice of Extraordinary General Meeting/Proxy Form  
 
    Kazia new collaboration with Dana-Farber Cancer Institute  
 
    Kazia AGM and closing date for director nominations  
 
    Kazia presents to H C Wainwright conference  
 
    Conversion of options  
 
    Kazia change in directors interests  
 
    Kazia change in directors interests  
 
    Kazia Appendix 4E  
 
    Kazia Annual Report to shareholders  
 
    Kazia Corporate Governance Statement  
 
    Kazia Appendix 4G  
 
    Change in substantial holding  
 
    Kazia's paxalisib awarded Orphan Drug Designation  
 
    Change in substantial holding  
 
    Kazia's paxalisib granted Fast Track Designation by FDA  
 
    Change in substantial holding  
 
    Change in substantial holding  
 
    Kazia's paxalisib obtains Rare Pediatric Disease Designation  
 
    Appendix 4C - quarterly  
 
    Change in substantial holding  
 
    Ceasing to be a substantial holder  
 
    Kazia presents to Hidden Gems ShareCafe Investor Webinar  
 
    Change in substantial holding  
 
    Kazia presentation to TKIRW  
 
    Expiry of options  
 
    Appendix 3Y Iain Ross  
 
    Appendix 2A conversion of options  
 
    Change of Director's Interest Notice x4  
 
    Kazia Appendix 2A  
 
    Change in substantial holding  
 
    Kazia Share Purchase Plan raises $1.8m  
 
    Kazia Share Purchase Plan extended  
 
    Kazia Share Purchase Plan reminder  
 
    Becoming a substantial holder  
 
    Change in substantial holding  
 
    Change in substantial holding  
 
    Kazia cleansing statement  
 
    Kazia share purchase plan  
 
    Cantrixil last patient visit  
 
    Kazia Appendix 2A  
 
    Kazia transcript of investor call  
 
    Change in substantial holding  
 
    Proposed issue of Securities - KZA  
 
    Proposed issue of Securities - KZA  
 
    Kazia placement and Share Purchase Plan  
 
    Trading Halt  
 
    Kazia paxalisib Phase II interim data  
 
    Change in substantial holding  
 
    Change in substantial holding  
 
    Kazia March 2020 newsletter  
 
    Completion of recruitment to paxalisib P2 GBM study  
 
    Change in substantial holding  
 
    Kazia change in directors interests SC and JG  
 
    Kazia Half Year Accounts and Chairman's letter  
 
    Appendix 3B and Appendix 3G - ESOP  
 
    Kazia presents at Biotech Showcase  
 
    Kazia receives $1.4m R&D cash rebate  
 
    Kazia EGM results  
 
    Change in substantial holding  
 
    ASX waiver on voting restrictions  
 
    Change in substantial holding  
 
    Kazia joins GBM Agile  
 
    Change in substantial holding  
 
    Change of directors interest notice - James Garner  
 
    Change of directors interest notice - Iain Ross  
 
    Kazia presents to Switzer Investment Conference  
 
    Kazia GDC-0084 investor call transcript  
 
    Appendix 3Y  
 
    Appendix 3Y  
 
    Ceasing to be a substantial holder  
 
    Trading Halt  
 
    Kazia Appendix 4G and Corporate Governance Statement  
 
    Kazia AGM webcast  
 
    Appendix 3B and Appendix 3Y  
 
    Results of Meeting  
 
    Kazia AGM presentations  
 
    Kazia notice of meeting for EGM  
 
    Becoming a substantial holder  
 
    Change in substantial holding  
 
    Change in substantial holding  
 
    Appendix 3B cleansing statement and disclosures  
 
    Kazia presents to AusBiotech Invest  
 
    Kazia raises $4 million  
 
    Trading Halt  
 
    Kazia Notice of Annual General Meeting/Proxy Form  
 
    Kazia September newsletter  
 
    MTD achieved in St Jude study in DIPG  
 
    Change in Directors interests - James Garner  
 
    Kazia Annual Report to shareholders  
 
    Kazia Appendix 4E  
 
    WHO selects provisional name for Kazia's GDC-0084  
 
    Kazia completes recruitment to Cantrixil Phase 1 trial  
 
    Kazia collaboration with MSK  
 
    Substantial shareholder change in interests  
 
    Appendix 3Y for 4 directors  
 
    Change in substantial shareholder interest  
 
    Kazia presents to Gold Coast Investment Showcase  
 
    Kazia June Newsletter  
 
    Kazia's GDC-0084 joins Alliance trial in brain cancer  
 
    BNYM substantial shareholder notice  
 
    Becoming a substantial holder  
 
    Top-line safety data from Kazia's GDC-0084 phase II study  
 
    Appendix 3Y James Garner  
 
    Amended Appendix 3Y Iain Ross  
 
    Appendix 3Y Iain Ross  
 
    Kazia presents Cantrixil Phase I data at AACR  
 
    Kazia sells stake in Noxopharm  
 
    Appendix 3B placement capacity  
 
    Kazia half-year report and Chairman's letter  
 
    Kazia presentation to Proactive Investors  
 
    Kazia receives $2.2m R&D cash rebate  
 
    Kazia presentation to Biotech Showcase  
 
    Appendix 3B amended  
 
    Appendix 3B  
 
    Appendix 3Y James Garner  
 
    Kazia Appendix 3Y  
 
    Change in directors' interests * 4  
 
    Appendix 3B and cleansing notice  
 
    Kazia SPP raises $0.8 million  
 
    Appendiz 3Y Iain Ross  
 
    Appendix 3B amendment  
 
    Kazia AGM recording  
 
    Appendix 3B & Cleansing Notice  
 
    AGM results  
 
    AGM presentations  
 
    Kazia November Newsletter  
 
    Kazia presents to AusBiotech Invest  
 
    GDC-0084 update  
 
    Becoming a substantial holder  
 
    Section 708 notice  
 
    Appendix 3B and Listing Rules disclosures  
 
    Kazia Share Purchase Plan  
 
    Kazia breast mets collaboration with Dana-Farber  
 
    Reinstatement to Official Quotation  
 
    Kazia raises $3.4m to progress R&D programs  
 
    Suspension from Official Quotation  
 
    Trading Halt  
 
    Presentation to Finance News Network Investor Event  
 
    Cantrixil Part A completion  
 
    Kazia Notice of Meeting  
 
    Kazia Annual Report to shareholders, Appx 4G, Corporate Governance Statement  
 
    Kazia change in interest of substantial shareholder  
 
    Kazia collaborates with St Jude Children's Research Hospital  
 
    Kazia attains Milestone 1 under Glioblast Purchase Agreement  
 
    Kazia Appendix 4E and financial report  
 
    Kazia files shelf registration statement with SEC  
 
    Kazia Shareholder Presentation  
 
    Kazia divests ATM program  
 
    Kazia shareholder information sessions UPDATE  
 
    Kazia change in interests of substantial shareholder  
 
    Kazia Shareholder Information Sessions  
 
    Kazia presents at Gold Coast Investment Showcase  
 
    Kazia releases preliminary Cantrixil Phase I data  
 
    Progress Report  
 
    Kazia Shareholder Newsletter  
 
    Kazia commences Phase II clinical study of GDC-0084  
 
    Kazia presentation to Proactive Investors CEO series  
 
    Notice of change in interests of substantial holder  
 
    Kazia responds to share trading on ASX and Nasdaq  
 
    Kazia receives FDA orphan drug designation for GDC 0084  
 
    Kazia Appendix 4D, Half yearly accounts and Chairmans letter  
 
    Kazia change of address  
 
    Kazia receives $4m R&D tax rebate  
 
    Kazia Appendix 3B  
 
    Notice of change of interests of substantial holder  
 
    Receipt of securities in Noxopharm Limited (NOX)  
 
    Kazia change of interests of substantial shareholder  
 
    Kazia presentation to Biotech Showcase